NCT04194190No Longer Available不适用
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
A single patient will be treated with Individual Patient TCR-Transduced PBL
详细描述
Background:
-Please refer to National Cancer Institute Surgery Branch (NCI-SB) protocol 18-C-0049, Amendment F.
Objective:
-Under Individual Patient Expanded Access, to treat a patient with metastatic breast cancer with autologous peripheral blood lymphocytes (PBL) that have been transduced with genes encoding T-cell receptors that recognize mutated neoantigens in the autologous cancer.
Eligibility:
研究设计
- 研究类型
- Expanded Access
入排标准
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
No Longer Available
不适用
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of PembrolizumabNCT04135092National Institutes of Health Clinical Center (CC)
尚未招募
2 期
First-line Replacement Maintenance of Envafolimab in Advanced NSCLCNon-Small-Cell LungNCT05465733First Affiliated Hospital Xi'an Jiaotong University25
招募中
2 期
Combination of TATE and PD-1 Inhibitor in Liver CancerHepatocellular CarcinomaGastric CancerNCT03259867Teclison Ltd.54
已完成
2 期
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)Renal Cell CarcinomaNCT02853344Merck Sharp & Dohme LLC275
招募中
2 期
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin LymphomaClassical Hodgkin LymphomaNCT04837859University of Cologne120